IPO - BIO-PATH HOLDINGS, INC.

Form Type: S-1/A

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: Update

Accession Number: 000110465925011965

Filing Summary: Bio-Path Holdings, Inc. filed an amendment to its registration statement (Form S-1/A) on February 12, 2025, to register a public offering of up to 13,003,901 shares of common stock. This offering includes pre-funded warrants and common warrants, aimed at enabling investors to purchase shares while minimizing dilution. The offering is structured as a best-efforts sale with an assumed combined public offering price of $0.769 per share. The proceeds from this offering will be utilized to fund clinical trials for their drug candidates targeting several types of cancers, including acute myeloid leukemia (AML). The lead drug candidate, BP1001, is in a Phase 2 trial combining with decitabine and venetoclax. Additionally, the company highlights rigorous safety data from previous studies, projecting further advancement in clinical development and the exploration of expedited FDA programs. The Inclusion of various warrants in the offering relates to regulatory compliance concerning stockholder approvals, which will hinge upon specific pricing conditions being met under Nasdaq rules. The offer is also marked by operational risk factors and an acknowledgment of significant competition in the oncology sector that might impact enrollment in clinical trials.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-21

Corporate Action: Ipo

Type: New

Accession Number: 000110465925004576

Filing Summary: Bio-Path Holdings, Inc. filed a registration statement on Form S-1 with the Securities and Exchange Commission on January 17, 2025. The filing pertains to a public offering of shares of its common stock, along with pre-funded warrants and common warrants. The company aims to raise capital by offering its securities to institutional and accredited investors. This offering is described as a best-efforts public offering where the total number of shares and associated warrants is yet to be determined, contingent upon the market conditions and investor demand. The company’s common stock is listed on the Nasdaq Capital Market under the symbol 'BPTH'. The funds raised will be used to support the company’s clinical development and general corporate purposes. The document includes details concerning the potential exercise of warrants, pricing conditions, and risks associated with the offering, reflecting the company's emerging growth status.

Document Link: View Document